The putative anti-atherogenic properties of PON1 stem from meta-analyses of human population studies that consistently show decreased PON1 activity to be associated with cardiovascular disease (CVD) risk [11,12,13]. The gene discussed is PON1; the disease is cardiovascular disorder.